Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP8825 Phase II Study-A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP8825 in Patients With Restless Legs Syndrome

Next Previous
X
Search
Trial Profile

ASP8825 Phase II Study-A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP8825 in Patients With Restless Legs Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Restless legs syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 20 Nov 2009 Based on the positive results of this trial, Astellas Pharma and XenoPort have submitted a new drug application to the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for the treatment of restless legs syndrome with gabapentin enacarbil.
    • 10 Mar 2009 Actual end date reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from active, no longer recruiting to completed, as completed by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top